Your browser doesn't support javascript.
loading
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Hong, David S; Morris, Van K; El Osta, Badi; Sorokin, Alexey V; Janku, Filip; Fu, Siqing; Overman, Michael J; Piha-Paul, Sarina; Subbiah, Vivek; Kee, Bryan; Tsimberidou, Apostolia M; Fogelman, David; Bellido, Jorge; Shureiqi, Imad; Huang, Helen; Atkins, Johnique; Tarcic, Gabi; Sommer, Nicolas; Lanman, Richard; Meric-Bernstam, Funda; Kopetz, Scott.
Afiliação
  • Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. dshong@mdanderson.org.
  • Morris VK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • El Osta B; Department of Hematology and Medical Oncology, Atlanta Veterans Affairs Medical Center, Emory University School of Medicine, Atlanta, Georgia.
  • Sorokin AV; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Overman MJ; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Piha-Paul S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kee B; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fogelman D; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bellido J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shureiqi I; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Huang H; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Atkins J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tarcic G; NovellusDx, Jerusalem, Israel.
  • Sommer N; Genentech, San Francisco, California.
  • Lanman R; Guardant Health, Redwood City, California.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Discov ; 6(12): 1352-1365, 2016 12.
Article em En | MEDLINE | ID: mdl-27729313
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sulfonamidas / Camptotecina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas B-raf / Cetuximab / Indóis Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Cancer Discov Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sulfonamidas / Camptotecina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas B-raf / Cetuximab / Indóis Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Cancer Discov Ano de publicação: 2016 Tipo de documento: Article